time

[키워드] 28-day mortality 95% CI acute respiratory syndrome addition adjusted hazard ratio Administered administration Admission Admissions adults hospitalized age Alanine alanine aminotransferase albumin Analysis Baltimore blood cell blood pressure body mass body mass index C-reactive protein Chain Reaction Charlson Comorbidity Index clinical Clinical improvement clinical trial Cohort Combination Comorbidity Complete conducted Control controls coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroid corticosteroid treatment Corticosteroids covariate COVID-19 death deaths decrease did not reduce dimerized Dimerized plasmin fragment D Effectiveness exposure faster filtration rate finding fraction glomerular filtration rate hazard ratio Health Organization health system hospital hospital discharge hospitalized patient hospitalized patients Importance improvement individual individuals infected individual infected individuals Infection interquartile range lymphocyte Lymphocyte count matched controls measure median median age men Mortality mortality rate multicenter objective outcome oxygen oxygen saturation participant Patient patients patients hospitalized Peripheral blood Point polymerase chain polymerase chain reaction Population Primary outcome Propensity score proportion pulse receipt receive recipient reduced Relevance Remdesivir Research respiratory respiratory rate Result retrospective secondary outcome setting severity Sex statistically significant temperature the median Therapies time treated Treatment Washington White blood cell with COVID-19 World Health Organization
[DOI] 10.1001/jamanetworkopen.2021.3071 PMC 바로가기 [Article Type] Research